
    
      All subjects will receive a dose of the vaccine that they received in the primary study
      (100382), approximately 4 years after the first dose. Blood samples will be taken before and
      after the administration of the vaccine dose to evaluate the anti-HAV and anti-HBs antibody
      response.
    
  